Sulfur mustard-stimulated protease: a target for antivesicant drugs.
One of the mechanisms of the skin blistering effect (vesication) of sulfur mustard (bis-(2-chloroethyl)sulfide, HD) is believed to be via the stimulation of specific protease(s) at the dermal-epidermal junction. Cultured normal human epidermal keratinocytes (NHEK) were used as a model to study and characterize protease stimulated by the mustards 2-chloroethyl ethyl sulfide (CEES), 2-chloro-N-(2-chloroethyl)-N-methylethanamine hydrochloride (nitrogen mustard, HN(2)) and HD. The results obtained using a chromozym (TRY) peptide substrate protease assay revealed the optimum mustard concentrations and time for protease stimulation to be about 200 microM (CEES), 100 microM (HN(2)) and 100 microM (HD) and 16 h. The mustard-stimulated protease was membrane bound and was inhibited by adding a Ca(2+) chelator (either 2 mM EGTA (ethylene glycol-bis(amino ethyl ether) N,N,N',N' tetraacetic acid) or 50 microM BAPTA AM (1,2-bis(z-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid, tetraacetoxy methyl ester) alone or in combination), a serine protease inhibitor diisopropyl fluoro-phosphate (DFP, 1 mM), or a protein synthesis inhibitor cycloheximide (35 microM) in the extracellular medium. These results suggest that mustard toxicity may involve the stimulation of trypsin/chymotrypsin-like serine protease, dependent on Ca(2+) and new protein synthesis. Protein purification by gel exclusion and hydrophobic chromatography produced a 70-80 kDa protease, which had an amino acid sequence homologous with a mammalian-type bacterial serine endopeptidase. Based on this information, research is in progress to identify the protease stimulated by HD in NHEK and to determine whether its inhibitors are useful as prospective antivesicant drugs.
Ray
Prabhati
P
Biology Department, Division of Experimental Therapeutics, Walter Reed Army Institute of Research, Washington, DC 20307-5100, USA. prabhati.ray@amedd.army.mil
Chakrabarti
A K
AK
Broomfield
C A
CA
Ray
R
R
D000595:Amino Acid Sequence; D001768:Blister / Q000139:chemically induced* / Q000503:physiopathology; D002478:Cells, Cultured; D002614:Chelating Agents / Q000494:pharmacology; D002848:Chromatography, DEAE-Cellulose; D002852:Chromatography, Ion Exchange; D003513:Cycloheximide / Q000494:pharmacology; D003879:Dermatologic Agents / Q000633:toxicity*; D004359:Drug Therapy, Combination; D004533:Egtazic Acid / Q000031:analogs & derivatives* / Q000494:pharmacology; D006801:Humans; D007531:Isoflurophate / Q000494:pharmacology; D015603:Keratinocytes / Q000187:drug effects* / Q000201:enzymology / Q000473:pathology; D008466:Mechlorethamine / Q000494:pharmacology; D008954:Models, Biological; D009151:Mustard Gas / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000633:toxicity*; D011041:Poisoning / Q000517:prevention & control; D011480:Protease Inhibitors / Q000494:pharmacology; D012697:Serine Endopeptidases / Q000737:chemistry / Q000302:isolation & purification / Q000378:metabolism
D002614:Chelating Agents; D003879:Dermatologic Agents; D011480:Protease Inhibitors; D007531:Isoflurophate; C070379:1,2-bis(2-aminophenoxy)ethane N,N,N',N'-tetraacetic acid acetoxymethyl ester; D008466:Mechlorethamine; D004533:Egtazic Acid; C031278:2-chloroethyl ethyl sulfide; D003513:Cycloheximide; D012697:Serine Endopeptidases; D009151:Mustard Gas